Simonn Pimstone News Today

Cantor Fitzgerald reissued their overweight rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report released on Tuesday, Benzinga reports. The firm currently has a $58.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued research reports about the company. StockNews.com initiated coverage on Xenon Pharmaceuticals in […]

Cantor Fitzgerald reaffirmed their overweight rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $58.00 price target on the biopharmaceutical company’s stock. XENE has been the topic of several other research reports. Stifel Nicolaus lifted their price target […]

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options. Analyst Upgrades and Downgrades A number of analysts have recently issued reports […]

Knott David M Jr lessened its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 32.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 40,000 shares of the biopharmaceutical company’s stock after selling 19,500 shares during the quarter. Knott David M […]

StockNews.com assumed coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research report report published on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Several other analysts have also commented on XENE. Cantor Fitzgerald assumed coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, April […]

StockNews.com began coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently issued reports on XENE. Wedbush reiterated an outperform rating and set a $47.00 price objective […]

Moran Wealth Management LLC purchased a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 67,613 shares of the biopharmaceutical company’s stock, valued at approximately $2,420,000. Moran Wealth Management LLC owned about 0.11% of Xenon […]

Victory Capital Management Inc. acquired a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 28,190 shares of the biopharmaceutical company’s stock, valued at approximately $1,009,000. Several other large investors also recently modified their holdings of XENE. […]

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) – Equities research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Xenon Pharmaceuticals in a research note issued on Tuesday, July 11th. Cantor Fitzgerald analyst C. Duncan expects that the biopharmaceutical company will post earnings per share of ($2.42) for the year. Cantor Fitzgerald currently has […]

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders purchased 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the typical daily volume of 165 put options. Wall Street Analyst Weigh In A number of brokerages have weighed […]